SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-043717
Filing Date
2021-08-12
Accepted
2021-08-12 10:35:49
Documents
17
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tals-8k_20210812.htm   iXBRL 8-K 37132
2 EX-99.1 tals-ex991_6.htm EX-99.1 98815
3 GRAPHIC gwpe3mueayuh000003.jpg GRAPHIC 3469
4 GRAPHIC gwpe3mueayuh000004.jpg GRAPHIC 3469
5 GRAPHIC gwpe3mueayuh000002.jpg GRAPHIC 3469
6 GRAPHIC gwpe3mueayuh000001.jpg GRAPHIC 3469
  Complete submission text file 0001564590-21-043717.txt   295001

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA tals-20210812.xsd EX-101.SCH 5764
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20210812_lab.xml EX-101.LAB 19482
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20210812_pre.xml EX-101.PRE 11618
10 EXTRACTED XBRL INSTANCE DOCUMENT tals-8k_20210812_htm.xml XML 3553
Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 211165953
SIC: 2836 Biological Products, (No Diagnostic Substances)